Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocol.

Schoemaker CG, Armbrust W, Swart JF, Vastert SJ, van Loosdregt J, Verwoerd A, Whiting C, Cowan K, Olsder W, Versluis E, van Vliet R, Fernhout MJ, Bookelman SL, Cappon J, van den Berg JM, Schatorjé E, Muller PCEH, Kamphuis S, de Boer J, Lelieveld OTHM, van der Net J, Jongsma KR, van Rensen A, Dedding C, Wulffraat NM.

Pediatr Rheumatol Online J. 2018 Sep 15;16(1):57. doi: 10.1186/s12969-018-0276-3. Review.

2.

PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation.

Petrelli A, Mijnheer G, van Konijnenburg DPH, van der Wal MM, Giovannone B, Mocholi E, Vazirpanah N, Broen JC, Hijnen D, Oldenburg B, Coffer PJ, Vastert SJ, Prakken BJ, Spierings E, Pandit A, Mokry M, van Wijk F.

J Clin Invest. 2018 Sep 10. pii: 96107. doi: 10.1172/JCI96107. [Epub ahead of print]

3.

Transcriptional and epigenetic profiling of nutrient-deprived cells to identify novel regulators of autophagy.

Peeters JGC, Picavet LW, Coenen SGJM, Mauthe M, Vervoort SJ, Mocholi E, de Heus C, Klumperman J, Vastert SJ, Reggiori F, Coffer PJ, Mokry M, van Loosdregt J.

Autophagy. 2018 Sep 11:1-15. doi: 10.1080/15548627.2018.1509608. [Epub ahead of print]

PMID:
30153076
4.

Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study.

van Dijkhuizen EHP, Aidonopoulos O, Ter Haar NM, Pires Marafon D, Magni-Manzoni S, Ioannidis YE, Putignani L, Vastert SJ, Malattia C, De Benedetti F, Martini A.

Rheumatology (Oxford). 2018 Oct 1;57(10):1752-1760. doi: 10.1093/rheumatology/key148.

PMID:
29931340
5.

Treating juvenile idiopathic arthritis to target: recommendations of an international task force.

Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Antón J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne P, Morgan EM, Quartier P, Ruperto N, Russo R, Saad-Magalhães C, Sawhney S, Scott C, Shenoi S, Swart JF, Uziel Y, Vastert SJ, Smolen JS.

Ann Rheum Dis. 2018 Jun;77(6):819-828. doi: 10.1136/annrheumdis-2018-213030. Epub 2018 Apr 11.

PMID:
29643108
6.

Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.

Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C, Gepstein R, Heiligenhaus A, Pilkington CA, Simonini G, Uziel Y, Vastert SJ, Wulffraat NM, Haasnoot AM, Walscheid K, Pálinkás A, Pattani R, Györgyi Z, Kozma R, Boom V, Ponyi A, Ravelli A, Ramanan AV.

Ann Rheum Dis. 2018 Aug;77(8):1107-1117. doi: 10.1136/annrheumdis-2018-213131. Epub 2018 Mar 28.

7.

Editorial: Toward Personalized Treatment for Systemic Juvenile Idiopathic Arthritis.

Vastert SJ, Nigrovic PA.

Arthritis Rheumatol. 2018 Aug;70(8):1172-1174. doi: 10.1002/art.40501. Epub 2018 Jun 29. No abstract available.

PMID:
29569852
8.

The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey.

Jeyaratnam J, Ter Haar NM, Lachmann HJ, Kasapcopur O, Ombrello AK, Rigante D, Dedeoglu F, Baris EH, Vastert SJ, Wulffraat NM, Frenkel J.

Pediatr Rheumatol Online J. 2018 Mar 21;16(1):19. doi: 10.1186/s12969-018-0235-z.

9.

Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients.

Schoemaker CG, van Dijkhuizen EHP, Vastert SJ.

Pediatr Rheumatol Online J. 2018 Feb 15;16(1):13. doi: 10.1186/s12969-018-0229-x. No abstract available.

10.

Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis.

Ter Haar NM, Tak T, Mokry M, Scholman RC, Meerding JM, de Jager W, Verwoerd A, Foell D, Vogl T, Roth J, Leliefeld PHC, van Loosdregt J, Koenderman L, Vastert SJ, de Roock S.

Arthritis Rheumatol. 2018 Jun;70(6):943-956. doi: 10.1002/art.40442. Epub 2018 May 7.

PMID:
29426067
11.

Patient's experiences with the care for juvenile idiopathic arthritis across Europe.

van Dijkhuizen EHP, Egert T, Egert Y, Costello W, Schoemaker C, Fernhout M, Kepic M, Martini A, Scala S, Rotstein-Grein I, Vastert SJ, Wulffraat NM.

Pediatr Rheumatol Online J. 2018 Feb 8;16(1):10. doi: 10.1186/s12969-018-0226-0.

12.

Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative.

Kuemmerle-Deschner JB, Hansmann S, Wulffraat NM, Vastert SJ, Hens K, Anton J, Avcin T, Martini A, Koné-Paut I, Uziel Y, Ravelli A, Wouters C, Shaw D, Özen S, Eikelberg A, Prakken BJ, Ruperto N, Horneff G, Constantin T, Beresford MW, Sikken M, Foster HE, Haug I, Schuller S, Jägle C, Benseler SM.

Ann Rheum Dis. 2018 Mar;77(3):319-327. doi: 10.1136/annrheumdis-2017-211904. Epub 2017 Oct 11.

PMID:
29021237
13.

Review: Enhancers in Autoimmune Arthritis: Implications and Therapeutic Potential.

Peeters JGC, Vastert SJ, van Wijk F, van Loosdregt J.

Arthritis Rheumatol. 2017 Oct;69(10):1925-1936. doi: 10.1002/art.40194. Review. No abstract available.

14.

European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative.

Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, Kenet G, Koné-Paut I, Lahdenne P, Marks SD, McCann L, Pilkington CA, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert SJ, Wulffraat NM, Ozen S, Brogan P, Kamphuis S, Beresford MW.

Ann Rheum Dis. 2017 Oct;76(10):1637-1641. doi: 10.1136/annrheumdis-2016-211001. Epub 2017 May 4. Review.

PMID:
28473426
15.

The human microbiome and juvenile idiopathic arthritis.

Verwoerd A, Ter Haar NM, de Roock S, Vastert SJ, Bogaert D.

Pediatr Rheumatol Online J. 2016 Sep 20;14(1):55. doi: 10.1186/s12969-016-0114-4. Review.

16.

Autoimmune disease-associated gene expression is reduced by BET-inhibition.

Peeters JG, Vervoort SJ, Mijnheer G, de Roock S, Vastert SJ, Nieuwenhuis EE, van Wijk F, Prakken BJ, Mokry M, van Loosdregt J.

Genom Data. 2015 Nov 7;7:14-7. doi: 10.1016/j.gdata.2015.11.004. eCollection 2016 Mar.

17.

Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat NM, Vastert SJ.

Pediatr Rheumatol Online J. 2015 Dec 3;13:55. doi: 10.1186/s12969-015-0055-3. Review.

18.

Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression.

Peeters JG, Vervoort SJ, Tan SC, Mijnheer G, de Roock S, Vastert SJ, Nieuwenhuis EE, van Wijk F, Prakken BJ, Creyghton MP, Coffer PJ, Mokry M, van Loosdregt J.

Cell Rep. 2015 Sep 29;12(12):1986-96. doi: 10.1016/j.celrep.2015.08.046. Epub 2015 Sep 17.

19.

Self-Sustained Resistance to Suppression of CD8+ Teff Cells at the Site of Autoimmune Inflammation Can Be Reversed by Tumor Necrosis Factor and Interferon-γ Blockade.

Petrelli A, Wehrens EJ, Scholman RC, Prakken BJ, Vastert SJ, van Wijk F.

Arthritis Rheumatol. 2016 Jan;68(1):229-36. doi: 10.1002/art.39418.

20.

Recommendations for the management of autoinflammatory diseases.

ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, Cantarini L, Galeotti C, Grateau G, Hentgen V, Hofer M, Kallinich T, Kone-Paut I, Lachmann HJ, Ozdogan H, Ozen S, Russo R, Simon A, Uziel Y, Wouters C, Feldman BM, Vastert SJ, Wulffraat NM, Benseler SM, Frenkel J, Gattorno M, Kuemmerle-Deschner JB.

Ann Rheum Dis. 2015 Sep;74(9):1636-44. doi: 10.1136/annrheumdis-2015-207546. Epub 2015 Jun 24. Review.

21.

Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis.

Bulatović Ćalasan M, Vastert SJ, Scholman RC, Verweij F, Klein M, Wulffraat NM, Prakken BJ, van Wijk F.

Rheumatology (Oxford). 2015 Sep;54(9):1724-34. doi: 10.1093/rheumatology/kev101. Epub 2015 Apr 14.

PMID:
25877908
22.

Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.

van Dijkhuizen EH, Bulatović Ćalasan M, Pluijm SM, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, Wulffraat NM.

Pediatr Rheumatol Online J. 2015 Feb 18;13:5. doi: 10.1186/s12969-015-0002-3. eCollection 2015.

23.

Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever.

Giancane G, Ter Haar NM, Wulffraat N, Vastert SJ, Barron K, Hentgen V, Kallinich T, Ozdogan H, Anton J, Brogan P, Cantarini L, Frenkel J, Galeotti C, Gattorno M, Grateau G, Hofer M, Kone-Paut I, Kuemmerle-Deschner J, Lachmann HJ, Simon A, Demirkaya E, Feldman B, Uziel Y, Ozen S.

Ann Rheum Dis. 2015 Apr;74(4):635-41. doi: 10.1136/annrheumdis-2014-206844. Epub 2015 Jan 27. Review.

24.

Paediatric rheumatic disease: Diagnosing macrophage activation syndrome in systemic JIA.

Vastert SJ, Prakken BJ.

Nat Rev Rheumatol. 2014 Nov;10(11):640-2. doi: 10.1038/nrrheum.2014.143. Epub 2014 Sep 9.

PMID:
25201384
25.

Pathophysiology of JIA-associated uveitis.

Vastert SJ, Bhat P, Goldstein DA.

Ocul Immunol Inflamm. 2014 Oct;22(5):414-23. doi: 10.3109/09273948.2014.926937. Epub 2014 Jul 2. Review.

PMID:
24988139
26.

Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.

Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, Wulffraat NM.

Arthritis Rheumatol. 2014 Apr;66(4):1034-43. doi: 10.1002/art.38296.

27.

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.

Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, Kamphuis SS, Dolman KM, Swart JF, van den Berg JM, Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2015 Jul;74(7):1379-86. doi: 10.1136/annrheumdis-2013-204641. Epub 2014 Mar 18.

PMID:
24641940
28.

Periodic fever in MVK deficiency: a patient initially diagnosed with incomplete Kawasaki disease.

Thors VS, Vastert SJ, Wulffraat N, van Royen A, Frenkel J, de Sain-van der Velden M, de Koning TJ.

Pediatrics. 2014 Feb;133(2):e461-5. doi: 10.1542/peds.2012-1372. Epub 2014 Jan 27.

29.

Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis.

Rothmund F, Gerss J, Ruperto N, Däbritz J, Wittkowski H, Frosch M, Wulffraat NM, Wedderburn LR, Holzinger D, Gohar F, Vastert SJ, Brik R, Deslandre CJ, Melo-Gomes JA, Saad Magalhaes C, Barcellona R, Russo R, Gattorno M, Martini A, Roth J, Foell D; Paediatric Rheumatology International Trials Organisation (PRINTO).

Arthritis Care Res (Hoboken). 2014 Jun;66(6):949-55.

30.

Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients.

Ćalasan MB, den Boer E, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, Wulffraat NM.

Ann Rheum Dis. 2015 Feb;74(2):402-7. doi: 10.1136/annrheumdis-2013-203723. Epub 2013 Nov 28.

PMID:
24288013
31.

Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis.

Bulatović Calasan M, de Vries LD, Vastert SJ, Heijstek MW, Wulffraat NM.

Rheumatology (Oxford). 2014 Feb;53(2):307-12. doi: 10.1093/rheumatology/ket310. Epub 2013 Oct 24.

PMID:
24162034
32.

Anti-tumor necrosis factor α targets protein kinase B/c-Akt-induced resistance of effector cells to suppression in juvenile idiopathic arthritis.

Wehrens EJ, Vastert SJ, Mijnheer G, Meerding J, Klein M, Wulffraat NM, Prakken BJ, van Wijk F.

Arthritis Rheum. 2013 Dec;65(12):3279-84. doi: 10.1002/art.38132.

33.

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, Bader-Meunier B, Vastert SJ, Noseda E, D'Ambrosio D, Lecot J, Chakraborty A, Martini A, Chioato A; Paediatric Rheumatology International Clinical Trials Organisation.

Arthritis Rheum. 2012 Feb;64(2):557-67. doi: 10.1002/art.33342.

34.

Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.

van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM.

J Rheumatol. 2011 Jul;38(7):1441-6. doi: 10.3899/jrheum.100809. Epub 2011 Apr 1.

PMID:
21459936
35.

FOXP3+ CD4+ Tregs lose suppressive potential but remain anergic during transient inflammation in human.

Schadenberg AW, Vastert SJ, Evens FC, Kuis W, van Vught AJ, Jansen NJ, Prakken BJ.

Eur J Immunol. 2011 Apr;41(4):1132-42. doi: 10.1002/eji.201040363. Epub 2011 Mar 7.

36.

Decreased levels of sCD21 and sCD23 in blood of patients with systemic-juvenile arthritis, polyarticular-juvenile arthritis, and pauciarticular-juvenile arthritis.

Singh A, Vastert SJ, Prakken BJ, Illges H.

Rheumatol Int. 2012 Jun;32(6):1581-7. doi: 10.1007/s00296-011-1830-1. Epub 2011 Feb 17.

PMID:
21328056
37.

Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.

Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, Magni-Manzoni S, Insalaco A, Cortis E, van Solinge WW, Prakken BJ, Wulffraat NM, de Benedetti F, Kuis W.

Rheumatology (Oxford). 2010 Mar;49(3):441-9. doi: 10.1093/rheumatology/kep418. Epub 2009 Dec 17.

PMID:
20019066
38.

Systemic JIA: new developments in the understanding of the pathophysiology and therapy.

Vastert SJ, Kuis W, Grom AA.

Best Pract Res Clin Rheumatol. 2009 Oct;23(5):655-64. doi: 10.1016/j.berh.2009.08.003. Review.

39.

Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.

de Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, Prakken BJ.

Arthritis Rheum. 2009 Sep;60(9):2782-93. doi: 10.1002/art.24750.

40.

[Two children with severe complications following incomplete removal of a percutaneous endoscopic gastrostomy (PEG) catheter].

Haanstra HB, Vastert SJ, Vos GD, Pelleboer RA.

Ned Tijdschr Geneeskd. 2007 Mar 10;151(10):607-10. Dutch.

PMID:
17402654
41.

Hemophagocytosis during fludarabine-based SCT for systemic juvenile idiopathic arthritis.

Ferreira RA, Vastert SJ, Abinun M, Foster HE, Modesto C, Olivé T, Kuis W, Wulffraat NM.

Bone Marrow Transplant. 2006 Aug;38(3):249-51. Epub 2006 Jun 12. No abstract available.

PMID:
16770315
42.

The right circumscript populations.

Schadenberg AW, Vastert SJ, Jansen NJ, Prakken BJ.

Crit Care Med. 2005 Jun;33(6):1468; author reply 1469. No abstract available.

PMID:
15942402

Supplemental Content

Loading ...
Support Center